1. Longevity Health Holdings announces merger with True Health Inc. (THPlasma). 2. After merger, combined company trades as XAGE on Nasdaq. 3. THPlasma aims to expand from 2 to 5 centers and enhance profitability. 4. The merger supports overcoming U.S. plasma shortfall. 5. Longevity's recent mergers may enhance customer value proposition.

1. Aptorum Group merges with DiamiR Biosciences in an all-stock deal. 2. DiamiR becomes a wholly-owned subsidiary and focuses on brain health. 3. Shareholders will vote on the merger and potential reverse stock split. 4. The combined company aims to lead in biopharma services and blood-based diagnostics. 5. Merger expected to close in Q4 2025, enhancing revenue generation potential.

1. Monogram to be acquired by Zimmer Biomet for $4.04 per share. 2. Stockholders may receive up to $12.37 per share based on milestones. 3. Transaction expected to drive revenue growth by 2027 and beyond. 4. Zimmer Biomet aims to lead in fully autonomous orthopedic robotics. 5. Closure pending regulatory approvals and stockholder consent.

1. Sonnet is combining with Rorschach to create Hyperliquid Strategies Inc. 2. The new entity will manage $888 million in value including 12.6 million HYPE tokens. 3. Sonnet aims to leverage this partnership to enhance biotech asset funding. 4. The merger is subject to approval from Sonnet's stockholders and final closing conditions. 5. Sonnet will continue to focus on its biotech assets and develop SON-1010.

1. Pagaya expects Q2 2025 results to exceed prior guidance. 2. Focus on optimizing balance sheet to reduce capital costs. 3. No plans to issue equity or linked instruments soon. 4. Strong execution noted in financial performance for growth. 5. Final Q2 results will be reported on August 7, 2025.

1. Mesoblast reported $13.2 million gross revenue in Q1 post-launch of Ryoncil®. 2. Ryoncil® is the first FDA-approved MSC product for treating SR-aGvHD. 3. Coverage for Ryoncil® expanded to over 250 million lives in the U.S. 4. Seven years of orphan-drug exclusivity granted for Ryoncil® by the FDA. 5. Plans for a pivotal trial for adult SR-aGvHD patients are underway.

1. Talen Energy to acquire Moxie and Guernsey plants for $3.5 billion. 2. Transaction increases free cash flow per share by over 40% in 2026. 3. Acquisition enhances Talen's power generation capacity by 50%, reaching 60 TWh. 4. The plants are efficient and benefit from strong gas pipeline access. 5. Talen maintains balance sheet strength and plans $500 million in share repurchases.

1. MCRI reported Q2 2025 net revenue of $136.9 million, up 6.8%. 2. Net income increased 19.1% year-over-year, reaching $27 million. 3. Adjusted EBITDA rose 16.8% to $51.3 million, with margins improving. 4. Cash and equivalents totals $71.6 million; no credit facility borrowings. 5. Quarterly dividend announced at $0.30 per share, demonstrating strong capital return.

1. Galaxy Digital to report Q2 2025 financial results on August 5, 2025. 2. CEO Michael Novogratz will host an investor update conference call. 3. Galaxy is a leader in digital assets and data center infrastructure. 4. Company focuses on finance and artificial intelligence solutions. 5. Live webcast of the conference available for investors.

1. Denison discovered high-grade uranium outside the D1 lens at Gryphon. 2. Drill hole WR-837AD2 shows promising uranium grades for further exploration. 3. Gryphon deposit estimated to contain substantial indicated mineral resources. 4. Delineation program yields successful confirmation of existing geological model. 5. Future expansion targeted for high-grade mineralization areas at Gryphon.